Synergy Pharma: Sales Ramp Ignored Aug. 14, 2018 2:55 PM ET|13 comments | About: Synergy Pharmaceuticals, Inc. (SGYP), Includes: ESRX
Stone Fox Capital
Summary
Synergy Pharma continues a slow ramp of Turlance prescriptions. Significant cost controls helped cut the quarterly loss my nearly $10 million.
The Express Scripts deal for 2019 places the biotech on a path to a huge sales ramp by Q2'19.
Synergy Pharma (SGYP) has made several rallies towards $2, but the biotech stock hasn't held any gains despite improving prescription numbers for Trulance that treats IBS. The business developments during the last few months sets the stock up for a sustainable rally.
Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.